N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure
暂无分享,去创建一个
R. D. de Boer | W. Tay | T. Jaarsma | A. Voors | L. Ling | C. Lam | H. Ong | D. V. van Veldhuisen | A. Richards | P. van der Meer | F. Jaufeerally | D. Sim | T. Teng | J. Tromp | P. Yeo | G. Leong | P. S. D. Yeo | A. Richards
[1] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[2] Deepak L. Bhatt,et al. Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. , 2013, JACC. Heart failure.
[3] C. Frampton,et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.
[4] G. Navis,et al. Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction , 2006, Circulation.
[5] W. Paulus,et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation , 2016, European journal of heart failure.
[6] Eun-Seok Jeon,et al. Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry , 2011, Korean circulation journal.
[7] L. Foucan,et al. NT-proBNP, Cardiometabolic Risk Factors, and Nutritional Status in Hemodialysis Patients , 2017, International journal of nephrology.
[8] Antoni Bayes-Genis,et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.
[9] A. Keren,et al. Ethnic disparity in the clinical characteristics of patients with heart failure , 2015, European journal of heart failure.
[10] D. Lloyd‐Jones,et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2007, American heart journal.
[11] V. Cameron,et al. The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design. , 2013, Journal of cardiac failure.
[12] A. Hoes,et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. , 2013, Journal of the American College of Cardiology.
[13] C. Frampton,et al. Superior performance of N‐terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting , 2017, European journal of heart failure.
[14] Hans L Hillege,et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). , 2008, Archives of internal medicine.
[15] D. McManus,et al. The complex relationship of race to outcomes in heart failure with preserved ejection fraction. , 2015, The American journal of medicine.
[16] Alan S Maisel,et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. , 2006, American heart journal.
[17] J. Gardin,et al. Racial differences in incident heart failure among young adults. , 2009, The New England journal of medicine.
[18] Y. Chan,et al. Impact of race on morbidity and mortality in patients with congestive heart failure: a study of the multiracial population in Singapore. , 2009, International journal of cardiology.
[19] P. Ponikowski,et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.
[20] K. Swedberg,et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.
[21] Tiny Jaarsma,et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure , 2004, European journal of heart failure.
[22] P. Ponikowski,et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short‐term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial , 2014, European journal of heart failure.
[23] F. McAlister,et al. Ethnic differences in 1-year mortality among patients hospitalised with heart failure , 2011, Heart.
[24] Robert N. Doughty,et al. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.
[25] J. Sanderson,et al. Plasma brain natriuretic peptide — an independent predictor of cardiovascular mortality in acute heart failure , 1999, European journal of heart failure.
[26] B. Riegel,et al. Racial Differences in Clinical Treatment and Self‐Care Behaviors of Adults With Chronic Heart Failure , 2015, Journal of the American Heart Association.
[27] D. J. Veldhuisen,et al. Anaemia and renal dysfunction are independently associated with BNP and NT‐proBNP levels in patients with heart failure , 2007, European journal of heart failure.
[28] M. Kinoshita,et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.
[29] G. Lip,et al. Heart failure—the importance of ethnicity , 2004, European journal of heart failure.
[30] L. Jorde,et al. Genetic variation, classification and 'race' , 2004, Nature Genetics.
[31] Akshay S. Desai,et al. Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure , 2013, Circulation. Heart failure.
[32] J. Hollander,et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[33] C. Lam,et al. The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.
[34] P. Ponikowski,et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). , 2013, JACC. Heart failure.
[35] N. Bayley,et al. Failure , 1890, The Hospital.
[36] Y. Pinto,et al. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. , 2008, The American journal of cardiology.